- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00470665
Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients
May 7, 2007 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
An Open-Label, Concentration-Controlled, Randomized, 12-Month Study of Prograf + Rapamune + Corticosteroids Compared to Cyclosporine,USP (Modified) + Rapamune + Corticosteroids in High Risk Renal Allograft Recipients
The purpose of this study is to assess whether in high-risk kidney transplant patients (patients whose previous kidney transplant failed, have a high PRA lab test result or are of African-American descent) that a combination of Rapamune with Prograf and steroids will prevent acute rejection as well as Rapamune and cyclosporine and steroids.
Study Overview
Study Type
Interventional
Enrollment
460
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Patients of African-American descent or patient with a history of multiple transplants and/or patients with a high panel reactive antibody lab test with a renal transplant from a cadaveric donor, a living unrelated donor or a living-related mismatched donor.
- Age >= 13 years, weight >= 40 kg
- Women must have a negative pregnancy test at study entry
Exclusion criteria
- Multiple organ transplants or double kidney transplants (pediatric en-bloc or double adult)
- Active systemic infection, or localized major infection or known HIV
- Patients with residual kidney function >20 mL/min
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
First biopsy-confirmed acute rejection, patient death or graft loss in the first 12 months following transplantation. First occurence of kidney graft loss or patient death in the first 12 months following transplantation.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Study Completion
July 1, 2004
Study Registration Dates
First Submitted
May 7, 2007
First Submitted That Met QC Criteria
May 7, 2007
First Posted (Estimate)
May 8, 2007
Study Record Updates
Last Update Posted (Estimate)
May 8, 2007
Last Update Submitted That Met QC Criteria
May 7, 2007
Last Verified
May 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0468H1-903
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Allograft Recipients
-
National Taiwan University HospitalTerminatedHBsAg-positive Renal Allograft Recipients
-
Bristol-Myers SquibbRecruitingRenal Allograft RecipientsFrance, United States, Germany, Spain, United Kingdom, Italy, Netherlands, Belgium
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
-
University of RegensburgUniversity of Heidelberg Medical Center; Charite University, Berlin, Germany; Hannover Medical School and other collaboratorsUnknownPancreas Allograft Recipients w/wo Kidney TransplantationGermany
-
University of CincinnatiRoche Pharma AG; University of TennesseeCompletedAcute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant RecipientsUnited States, Canada
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.; Rho Federal... and other collaboratorsTerminatedCardiac Allograft Vasculopathy | Heart Transplant RecipientsUnited States
-
University of CincinnatiCompletedPrimary Renal AllograftUnited States
-
Andrew B AdamsBristol-Myers SquibbCompletedFailing Renal AllograftUnited States
-
Universidade Federal de PernambucoUnknownRenal Transplant RecipientsBrazil
-
Lawson Health Research InstituteAstellas Pharma Canada, Inc.CompletedRenal Transplant RecipientsCanada
Clinical Trials on Rapamune
-
University Medicine GreifswaldCompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug InteractionsGermany
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
St. Joseph's Healthcare HamiltonWithdrawn
-
University of ChicagoRecruitingPulmonary Fibrosis | COVID-19 Pneumonia | Long COVIDUnited States
-
National Eye Institute (NEI)Completed
-
University of California, San FranciscoWithdrawnSevere Combined Immunodeficiency | Stem Cell Transplant | Transplacental Maternal EngraftmentUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
PfizerCompletedRenal TransplantationArgentina
-
Fundacio PuigvertMinistry of Health, SpainCompleted
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States